Q4 2025 Trading Update

AI SummaryClose X

Shield Therapeutics plc reported positive operating cash flow in Q4 2025 and full-year 2025 total revenues of approximately $50 million, a significant increase from $32 million in the prior year. The company's key product, ACCRUFeR®, saw its revenues grow by 56% to approximately $46 million in 2025, driven by a 21% rise in average net selling price to $223 and a 33% increase in total prescriptions to around 199,000. ACCRUFeR® net revenues in Q4 2025 reached $13.5 million, with prescriptions at approximately 61,000. The company ended 2025 with $11.6 million in cash and cash equivalents and anticipates delivering an operating profit in 2026.

Disclaimer*

UK 100

Latest directors dealings